BRIM Biotechnology's EBIT per Share for the
three
months ended in Dec. 2025 was NT$-1.29.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-3.40.
During the past 3 years, the average EBIT per Share Growth Rate was -5.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -14.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for BRIM Biotechnology's EBIT per Share or its related term are showing as below:
TPE:6885'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -43.1 Med: -20.4 Max: -5.2
Current: -5.2
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of BRIM Biotechnology was -5.20% per year. The lowest was -43.10% per year. And the median was -20.40% per year.
TPE:6885's 3-Year EBIT Growth Rate is ranked worse than 75.72% of 1174
companies
in the Biotechnology industry
Industry Median: 15.4
vs TPE:6885: -5.20
BRIM Biotechnology (TPE:6885) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
BRIM Biotechnology EBIT per Share Related Terms
BRIM Biotechnology EBIT per Share Historical Data
* Premium members only.
The historical data trend for BRIM Biotechnology's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-3.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRIM Biotechnology (TPE:6885) has a EBIT per Share of NT$-3.40 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BRIM Biotechnology and its competitors. According to the industry distribution chart, BRIM Biotechnology ranks #889 out of 1174 companies in the Biotechnology industry, placing it in the top 75.7%.
Is BRIM Biotechnology's EBIT per Share too high?
BRIM Biotechnology's current EBIT per Share is NT$-3.40. Based on the distribution chart, BRIM Biotechnology ranks #889 out of 1174 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BRIM Biotechnology has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BRIM Biotechnology's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BRIM Biotechnology ranks #889 out of 1174 companies for EBIT per Share. This places BRIM Biotechnology in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,174 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BRIM Biotechnology and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRIM Biotechnology's current EBIT per Share is NT$-3.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRIM Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, BRIM Biotechnology (TPE:6885) is currently considered Possible Value Trap. The stock's GF Value™ is NT$486.91, compared to a current price of NT$21.75 — trading 95.5% below its estimated fair value. The current EBIT per Share is NT$-3.40. BRIM Biotechnology's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For BRIM Biotechnology (TPE:6885), the current EBIT per Share is NT$-3.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRIM Biotechnology (TPE:6885) Overvalued in 2026?
Based on GuruFocus' analysis, BRIM Biotechnology stock appears to be undervalued.
The current stock price of NT$21.75 is trading 95.5% below its estimated GF Value™ of NT$486.91.
GuruFocus considers BRIM Biotechnology to be Possible Value Trap.
Key valuation signals for TPE:6885:
EBIT per Share: NT$-3.40
GF Value™: NT$486.91 vs. price of NT$21.75 (95.5% below fair value)
No single metric tells the full story. See the TPE:6885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRIM Biotechnology Inc is engaged in the research and development of new drug translation, genetic testing services, research and development services in natural and engineering sciences, and medical laboratory services. The Group has two reportable operating segments: BRIM's main business is new drug translational development services, and Compass's main business is gene sequencing and testing technology services. It generates the majority of its revenue from the BRIM segment. Geographically, it operates in Taiwan, Japan, and the USA. It generates the majority of its revenue from Taiwan.
40GF Score
Get the complete analysis for TPE:6885
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6885 has been successfully added to your 
